FDA approves weight loss drug Zepbound to treat obstructive sleep apnea - KCCU
Zepbound, a weight loss drug by Eli Lilly & Co., is the first prescription medication approved by the FDA to treat obstructive sleep apnea (OSA) in adults with obesity. Studies show Zepbound, used with a reduced-calorie diet and exercise, significantly reduces OSA symptoms, including breathing pauses, compared to a placebo. The approval marks a significant advancement for OSA patients.
Highlighted Terms
Related News
Zepbound, a weight loss drug by Eli Lilly & Co., is the first prescription medication approved by the FDA to treat obstructive sleep apnea (OSA) in adults with obesity. Studies show Zepbound, used with a reduced-calorie diet and exercise, significantly reduces OSA symptoms, including breathing pauses, compared to a placebo. The approval marks a significant advancement for OSA patients.